Navigation Links
Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
Date:10/27/2011

, which the company plans to develop into orally administered drugs for major depression and other psychiatric disorders.

NSI-189 stimulated neurogenesis of human hippocampus-derived neural stem cells in- vitro. In mice, NSI-189 stimulated neurogenesis in the hippocampus and increased its volume. In humans, NSI-189 may reverse the human hippocampal atrophy seen in major depression and other disorders. This program has received significant support from both the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is conducting an ongoing FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  Neuralstem's first small molecule compound, NSI-189 is currently in a Phase I FDA-approved safety trial in major depr
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuralstem Announces Issuance of Core Technology Patent in Europe
2. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
3. Neuralstems ALS Trial on Clinical Hold
4. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
5. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
6. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
7. Neuralstem Updates ALS Clinical Trial Progress
8. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
9. Neuralstem Updates NSI-189 Major Depression Trial
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 15, 2014  Stephen Squires, CEO and founder ... Materials Corp (OTCQB:QTMM), will be speaking at the ... (RCQM) on December 16th, 2014. The RCQM launch continues ... in attracting top faculty and students and by inviting ... research. "We have a long association ...
(Date:12/13/2014)... DUBLIN , Dec. 11, 2014 Research ... announced the addition of the "Drug Injection ... http://photos.prnewswire.com/prnh/20130307/600769 ... treatment of an expanding list of health conditions, ... options that simplify the administration process and increase ...
(Date:12/13/2014)... , December 12, 2014 ... has announced the addition of the  "Global ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... (CO2) in the respiratory gasses during the ... care. Capnography provides information about CO2 production, ...
Breaking Medicine Technology:Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4Global Capnography Market 2015-2019: Key Vendors are Covidien, Masimo, Philips Healthcare, Smiths Medical and Welch Allyn 2Global Capnography Market 2015-2019: Key Vendors are Covidien, Masimo, Philips Healthcare, Smiths Medical and Welch Allyn 3
... TOKYO , February 9 ... 31, 2009 .,Net sales were 106.8 billion yen for the ... period last year. Operating income was 18.9 billion,yen , a 13.8% ... year,mainly due to increase in orders and productivity. Compared to the second,quarter ...
... , UITHOORN, The Netherlands , February ... (49) as CEO of Hoya Vision Care,Europe starting the 1st of ... who has been leading the European branch in the past 5 years. ... Mr. Werquin has 20 years experience in the optical industry ...
Cached Medicine Technology:Hoya Announces Third Quarter Financial Results 2New CEO for Hoya Vision Care Europe 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... YORK, Nov. 10 Reportlinker.com announces that ... in its catalogue. , Cancer ... http://www.reportlinker.com/p0161834/Cancer-Non-Hodgkin-Lymphoma.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life Science Analytics, ... the current drug pipeline. This report provides ...
... in the air, play an important role in the ... are one of the greatest sources of uncertainty in ... the most of European satellite capabilities to monitor them. ... on the ERS-2 satellite, the Advanced Along Track Scanning ...
... SEATTLE A woman is six times more likely to ... or multiple sclerosis than if a man in the relationship ... role gender played in so-called "partner abandonment." The study ... it would remain intact. The study confirmed earlier research ...
... blame, , TUESDAY, Nov. 10 (HealthDay News) -- While there are ... new study now suggests that extra weight in adolescence may increase ... Nov. 10 issue of Neurology , Harvard researchers found that ... of developing MS later in life compared to her slimmer peers. ...
... , , ... ------- ------- -------- ------- ------- ... (16)% $17,237 $20,199 (15)%, Income (Loss) from, Continuing, ... (22)% ($1,833) $1,095 -, Diluted EPS from, ...
... ... a major concern for many Americans and when the future of health ... doors in the United States. Consumers now have more options to consider ... have options than now. Easy Pha-max provides superior quality plant-based nutritional products ...
Cached Medicine News:Health News:Reportlinker Adds Cancer Non-Hodgkin Lymphoma 2Health News:Climate studies to benefit from 12 years of satellite aerosol data 2Health News:Men leave: Separation and divorce far more common when the wife is the patient 2Health News:Teen Obesity Ups MS Risk in Women 2Health News:Teen Obesity Ups MS Risk in Women 3Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 2Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 3Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 4Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 5Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 6Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 7Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 8Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 9Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 10Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 11Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 12Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 13Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 14Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 15Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 16Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 17Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 18Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 19Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 20Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 21Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 22Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 23Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 24Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 25Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 26Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 27Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 28Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 29Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 30Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 31
Inquire...
... Captia™ Mumps IgG Enzyme- linked Immunosorbent Assay ... quantitative determination of IgG antibody to Mumps ... may be used for the determination of ... may be used to demonstrate seroconversion or ...
The DSL 05-10-MUM Mumps IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Mumps virus in human serum. This assay is intended for in...
... of the TEG analyzer and the TEG analytical ... the formation and dissolution of the clot, showing ... ,Haemoscope's TEG analyzer is the only hemostasis analyzer ... and proven model developed by Prof. Helmut Hartert ...
Medicine Products: